Biophytis (BPTSY) has released an update.
Biophytis SA, a Paris-based biotech company, has reported significant progress in their drug development programs, particularly with their lead candidate BIO101 for treating obesity, sarcopenia, and respiratory diseases. The company announced the initiation of a new phase 2 clinical trial for obesity treatment and received FDA approval for their Investigational New Drug. Their financial report as of June 30, 2024, underscores the ongoing research and potential market growth, as they target a rapidly expanding obesity treatment market projected to reach $100 billion by 2030.
For further insights into BPTSY stock, check out TipRanks’ Stock Analysis page.
